NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
Similar Posts
TeenScreen: the Law Suits Begin
TeenScreen: the Law Suits Begin Mon, 13 Jun 2005 Newsworthy developments about the duo-drug promotion scam‹TeenScreen & TMAP: A. The first legal challenge against TeenScreen, the mental health screening scheme that is invading the public school system across the nation, declaring otherwise normal children to be mentally ill, has been…
House Votes to Prevent Pharma-tied Scientists on FDA Advisory Panels
House Votes to Prevent Pharma-tied Scientists on FDA Advisory Panels Thu, 9 Jun 2005 The House passed an amendment introduced by Congressman Maurice Hinchey (NY) to rein in pharmaceutical industry influence on FDA advisory panels whose recdommendations have resulted in the approval of lethal drugs. Below Merrill Goozner write: “The…
FDA Smoke & Mirrors Musical Chairs
FDA Smoke & Mirrors Musical Chairs Wed, 16 Feb 2005 Amidst widespread public criticism of the FDA’s role as facilitators in the marketing of lethal drugs that killed thousands of people, the Administration made several announcements incorporating terminology (such as: “we’re in an era of openness” “transparency”). But politically correct…
2/3 Institute of Medicine AIDS research panel have Conflicts of Interst – Assoc Press
2/3 Institute of Medicine AIDS research panel have Conflicts of Interst – Assoc Press Thu, 17 Mar 2005 On Feb 25, the New York Times reported that 10 of 32 FDA panelists determining whether to recommend that COX 2 painkillers should allowed to be marketed despite the documented increased risk…
Despite Undisclosed Deaths, 10 Heart Attacks FDA Allows Blood Substitute Experiment With No Conset
The Wall Street Journal reports: “The FDA is allowing Northfield [Laboratories, Inc] to test its blood substitute without the consent of the trauma patients, who often are unconscious.”
IOM Report Faults FDA Drug-Safety Process
A report by the Institute of Medicine is sharply critical of FDA’s drug safety monitoring system: "The report’s conclusions are striking and often damning – particularly when discussing the agency’s Center for Drug Evaluation and Research, known as C.D.E.R."